India’s Maxygen Expects Amgen Patent Suit Over G-CSF Compounds
This article was originally published in PharmAsia News
Indian biotech Maxygen says U.S.-based Amgen's recent acquisition of a patent for its G-CSF class of proteins could mean a legal fight between the two companies. Amgen obtained the patent June 3 for the granulocyte colony stimulating factor, a natural protein important in production of white blood cells. Maxygen's Maxy-G34 belongs to that protein class and has a patent for its compound until 2021. The drug is currently in Phase II trials and the company expects Amgen to sue once the U.S. firm begins selling its own G-CSF compound. (Click here for more
You may also be interested in...
Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation.
New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.
After launching a biosimilar to Avastin (bevacizumab) in India, Cadila Pharma has now also launched rituximab and teriparatide biosimilars in its domestic market.